4,564 followers
RT @FrontOncology: New research: Advances in the treatment of relapsed/refractory marginal zone lymphoma: Marginal zone lymphoma (MZL) is t…
RT @FrontOncology: New research: Advances in the treatment of relapsed/refractory marginal zone lymphoma: Marginal zone lymphoma (MZL) is t…
RT @FrontOncology: New research: Advances in the treatment of relapsed/refractory marginal zone lymphoma: Marginal zone lymphoma (MZL) is t…
New research: Advances in the treatment of relapsed/refractory marginal zone lymphoma: Marginal zone lymphoma (MZL) is the second most common subtype of inert B-cell non-Hodgkin’s lymphoma, accounting for 5–15% of non-Hodgkin’s lymphoma cases.… https://t.c